| |
HR (95%CI) |
P |
HR 95%CI 1 |
Pa |
| Sex Male vs. female |
0.709 (0.414-1.320) |
0.307 |
|
|
| Age >40 years vs. <40 years |
1.25 (.733-2.125) |
0.414 |
|
|
| IDU vs. other transmission group |
1.23 (0.640-2.38) |
0.540 |
|
|
| cART starting year
2004-2005 vs. 2006-2009 |
1.860 (1.066-3.247) |
0.029 |
1.807 (1.028-3.176) |
0.040 |
| HCV and/or HBV-coinfection vs. HIV monoinfection |
1.976 (1.174-3.328) |
0.010 |
1.608 (0.924-2.797) |
0.093 |
| CD4+ cell count <200/mm3 vs. >200/mm3 |
1.342 (0.782-2.302 |
0.285 |
|
|
| HIV RNA >100.000 cop/ml vs. <100.000 cop/ml |
0.832 (0.489-1.413) |
0.496 |
|
|
| TDF + 3TC/FTC backbone |
0.613 (0.362-1.037) |
0.068 |
|
|
| ABC + 3TC backbone |
1.290 (0.630-2.650) |
0.481 |
|
|
| PI vs. NNRTI-based starting regimen |
2.118 (1.187-3.779) |
0.011 |
1.893 (0.1029-3.485) |
0.040 |
1. A Cox regression analysis, using a step-forward selection method, was performed to indentify variables associated to treatment outcome. Variables with a P value ≤
0.1 are retained in the regression equation. Relative risks are expressed as hazard ratios (HR) and 95% confidence intervals (CI)
ABC, abacavir; AZT, zidovudine; cART: combined antiretroviral treatment; ddI. didanosine; d4T. Stavudine; FTC, Emtricitabine; IDU, intravenous drug user; 3TC,
lamivudine; NNRTI, non-nucleosida reverse transcriptase inhibitor; R, ritonavir-boosted; PI, protease inhibitor; TDF, tenofovir |
